ALK and non-small cell lung carcinoma: Additionally, brain metastases (BMs) occur in 40–50% of patients with advanced NSCLC [5], particularly in those with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) oncogene mutations [6].